Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Cellectis S.A. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 70 | 57 | −13 |
| Shares | 15.4M | 15.2M | −200.9K (−1.3%) |
| Value | $194.1M | $123.7M | −$70.3M (−36.2%) |
New holders (10)
Institutions that held Cellectis S.A. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Long Focus Capital Management, LLC | 1,156,346 | $9.39M | 2.56% |
| Hudson Bay Capital Management LP | 115,000 | $934.0K | 0.01% |
| Trexquant Investment LP | 33,800 | $274.0K | 0.02% |
| Vident Investment Advisory, LLC | 21,529 | $175.0K | 0.00% |
| Envestnet Asset Management Inc | 17,196 | $140.0K | 0.00% |
| Geneos Wealth Management Inc. | 10,000 | $81.0K | 0.00% |
| Marshall Wace, LLP | 5,484 | $44.0K | 0.00% |
| Aquatic Capital Management LLC | 2,900 | $24.0K | 0.05% |
| TD Waterhouse Canada Inc. | 360 | $2.98K | 0.00% |
| Koshinski Asset Management, Inc. | 200 | $1.62K | 0.00% |
Sold out (23)
Institutions that held Cellectis S.A. at the end of Q3 2021 and filed for Q4 2021 without it.